Advanced therapy for pulmonary arterial hypertension due to congenital heart disease: A clinical perspective in a new therapeutic era

Netherlands Heart Journal

Volumn 19, Issue 12, 2011, Pages 509-513

  Schuuring, M J ^a,b   Boekholdt, S M ^a   Windhausen, A ^a   Bouma, B J ^a   Groenink, M ^a   Keijzers, M ^c   de Winter, R J ^a   Koolbergen, D R ^a   Blom, N A ^d   Mulder, B J M ^a,b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c Department of Orthopaedic Surgery   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; PROSTACYCLIN; SILDENAFIL;

ADULT; ARTICLE; BLALOCK TAUSSIG SHUNT; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONGENITAL HEART DISEASE; DRUG RESPONSE; EISENMENGER COMPLEX; ELECTROCARDIOGRAPHY; FEMALE; FONTAN PROCEDURE; HEART ATRIUM SEPTUM DEFECT; HEART CATHETERIZATION; HUMAN; LUNG EMBOLISM; MALE; MITRAL VALVE REGURGITATION; PULMONARY HYPERTENSION; SYSTOLIC HEART MURMUR; TACHYCARDIA; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME; TRICUSPID VALVE REGURGITATION;

EID: 83155168545     PISSN: 15685888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12471-011-0218-x     Document Type: Article

References (17)

1. Duffels MGJ, Engelfriet PM, Berger RMF, et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. Int J Cardiol. 2007;120(2):198-204.
2. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S43-54.
3. Schuuring MJ, Vis JC, Duffels MG, et al. Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan. Ther Clin Risk Manag. 2010;6:359-66.
4. Galiè N, Beghetti M, Gatzoulis M, et al. Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigator. Bosentan therapy in patients with Eisenmenger Syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114:48-54.
5. Palazzini M, Manes A, Romanazzi S, et al. Effects of sildenafil treatment in patients with pulmonary hypertension associated with congenital cardiac shunts. Eur Heart J. 2007;28:308.
6. Mukhopadhyay S, Sharma M, Ramakrishnan S, et al. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. Circulation. 2006;114(17):1807-10.
7. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30(20):2493-537.
8. Duffels MGJ, Vis JC, van Loon RLE, et al. Down patients with Eisenmenger syndrome: is bosentan treatment an option? Int J Cardiol. 2009;134(3):378-83.
9. Vis JC, Duffels MG, Mulder P, et al. Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease. Int J Cardiol. 2011.
10. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2000;161(2 Pt 1):487-92.
11. Schuuring M, Bouma B, Cordina R, et al. Treatment of Segmental Pulmonary Artery Hypertension in Adults with Congenital Heart Disease. Int J Cardiol. 2011;In press.
12. Galiè N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY Study). Lancet. 2008;371:2093-100.
13. Inai K, Nakanishi T, Nakazawa M. Clinical correlation and prognostic predictive value of neurohumoral factors in patients late after the Fontan operation. Am Heart J. 2005;150(3):588-94.
14. Schuuring MJ, Vis JC, Bouma BJ, et al. Rationale and design of a trial on the role of bosentan in Fontan patients: improvement of exercise capacity? Contemp Clin Trials. 2011.
15. Schuuring MJ, Bolmers PPM, Mulder BJM, et al. Right ventricular function declines after cardiac surgery in adult patients with congenital heart disease. Int J Cardiovasc Imaging. 2011.
16. Bond BR, Dorman BH, Clair MJ, et al. Endothelin-1 during and after cardiopulmonary bypass: association to graft sensitivity and postoperative recovery. J Thorac Cardiovasc Surg. 2001;122(2):358-64.
17. Joffs C, Walker CA, Hendrick JW, et al. Endothelin receptor subtype A blockade selectively reduces pulmonary pressure after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2001;122(2):365-70.